{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:10:57Z","timestamp":1788768657250,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Chronic myeloid leukemia presents unique management challenges in resource-limited settings such as Pakistan, where access to advanced molecular monitoring and newer tyrosine kinase inhibitors remains limited. This study evaluates the outcomes in patients with chronic myeloid leukemia in Pakistan, where first-generation tyrosine kinase inhibitors remain the primary mode of treatment due to the lack of newer interventions and insufficient molecular surveillance facilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed 73 patients with chronic myeloid leukemia treated at the Indus Hospital and Health Network, Karachi, Pakistan, between 2018 and 2025. Patients were stratified according to the European Treatment and Outcome Study long-term survival score, and treatment responses were compared using hematologic and molecular remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The proportion of males and females was almost equal. Conventional karyotypes were observed in 92.9% of cases. With imatinib as the first-line therapy, optimal response and treatment failure was observed in 31.3% and 45.3% cases, respectively. A lower complete hematologic response was associated with intermediate-risk scores and atypical fluorescence in situ hybridization results. The intent to change therapy was found to be a powerful predictor of better overall response (adjusted odds ratio: 23.620,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      -value: 0.0001). Only two patients transitioned to blast crisis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although there are promising trends of improvement in progression-free survival, the high rates of treatment failure as well as the lack of access to advanced treatment regimens and monitoring remain major concern. Strengthening public\u2013private collaborations and international partnerships is essential to ensure equitable access to advanced therapies and improve long-term outcomes in patients with chronic myeloid leukemia in low- and middle-income countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03000605261454643","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:43:28Z","timestamp":1781145808000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic myeloid leukemia in resource-limited settings: Navigating treatment challenges amid limited tyrosine kinase inhibitor access"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7323-4379","authenticated-orcid":false,"given":"Zunaira","family":"Aamir","sequence":"first","affiliation":[{"name":"Department of Clinical Hematology, Indus Hospital and Health Network (IHHN), Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Kaleem","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jinnah Medical and Dental College (JMDC), Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Jawad","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Cytogenetics Clinical Laboratories, Indus Hospital and Health Network (IHHN), Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqsa","family":"Hafeez","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Indus Hospital and Health Network (IHHN), Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambar","family":"Jabeen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indus Hospital and Health Network (IHHN), Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Ambreen","family":"Zehra","sequence":"additional","affiliation":[{"name":"Department of Cytogenetics Laboratory, Indus Hospital and Health Network (IHHN), Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-0694","authenticated-orcid":false,"given":"Neelum","family":"Mansoor","sequence":"additional","affiliation":[{"name":"Department of Pathology, Jinnah Medical and Dental College (JMDC), Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_3_7_3_2","first-page":"145","volume-title":"Chronic Myeloid Leukemia. Hematologic Malignancies","author":"Baccarani M","year":"2021","unstructured":"Baccarani M, Gugliotta G, Castagnetti F, et\u00a0al. A review and an update of European LeukemiaNet recommendations for the management of chronic myeloid leukemia. In: Hehlmann R (eds) Chronic Myeloid Leukemia. Hematologic Malignancies. Springer International Publishing, 2021, pp. 145\u2013158."},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.4103\/JLP.JLP_60_17"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.4137\/CMBD.S10578"},{"key":"e_1_3_7_6_2","first-page":"1039","article-title":"Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era","volume":"10","author":"Usmani S","year":"2009","unstructured":"Usmani S, Yunus S, Jamal Y. Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era. Asian Pac J Cancer Prev 2009; 10: 1039\u20131040.","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132148"},{"key":"e_1_3_7_8_2","first-page":"286","article-title":"Dilemmas in the diagnosis and management of CML in Pakistan","volume":"41","author":"Khan S","year":"2024","unstructured":"Khan S, Sabar MF, Akbar M, et\u00a0al. Dilemmas in the diagnosis and management of CML in Pakistan. Turk J Haematol 2024; 41: 286\u2013287.","journal-title":"Turk J Haematol"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00132"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.47391\/JPMA.20817"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01625-x"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02606-6"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.580759"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-024-06910-9"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7054"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2023.03.002"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110847"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213557"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011322"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19068"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24478"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2518028"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1172910"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000050"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.01.002"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8603-5-19"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3980-3"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01205-5"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13843"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0220"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16894"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261454643","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605261454643","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261454643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:59:08Z","timestamp":1788767948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605261454643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/03000605261454643"],"URL":"https:\/\/doi.org\/10.1177\/03000605261454643","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"03000605261454643"}}